Skip to main content
11 Sep 2020
9 Sep 2020
Final Phase II Results for UCB’s Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances
Read More
4 Sep 2020
31 Aug 2020
Phase 3 data on VIMPAT[®] (lacosamide) in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
Read More
28 Aug 2020
21 Aug 2020
10 Aug 2020
Acquisitions and disposals of own shares
Read More
5 Aug 2020
CIMZIA[®] is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose for Patients Across the Full Axial Spondyloarthritis Spectrum
Read More
30 Jul 2020
Acquisitions and disposals of own shares
Read More
30 Jul 2020
Subscribe to
